Pioneering Therapeutics Targeting Cellular Stress Pathways

Ribon is dedicated to the discovery and development of first-in-class small molecule inhibitors to block cancer cells' fundamental ability to survive under stress.

Learn More

Our Approach

Ribon explores novel areas of disease biology and uses deep expertise in drug discovery to advance its pipeline.

Learn More

Our Targets

Our platform enables us to develop first-in-class therapeutics targeting a wide variety of enzymes that use NAD+ as substrate.

Learn More
Jan 4

Press Release

Ribon Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer

Learn More
Join our team of experts.
Find Out More